Objective:To assess the efficacy and safety of MitraClip versus surgery in treatment of mitral regurgitation(MR). Methods:The Pub Med

Embase

Cochrane Library

CNKI

VIP and Wan Fang were electronically searched from inception to November 2015 for all the randomized controlled trial and prospective cohort study with MitraClip and surgical treatment of mitral regurgitation. Related journals and the related references were also searched and tracked. Results:A total of five elected studies involving 763 patients were included. Meta-analysis showed that:there was no statistically significant difference in the one-year survival rates(RR=0.985

95%CI=0.933 to 1.040

P=0.576)and 30-day mortality(RR=0.513

95%CI=0.190 to 1.384

P=0.188). There was no statistically significant difference in the one-year NYHA Class III/IV

acute kidney injury events

neurological events and30-day major adverse events. The post-procedure residual MR severity ≤2+ events(RR=0.858

95%CI=0.796 to 0.926

P=0.000)and the blood transfusion events(RR=0.303

95%CI=0.197 to 0.464

P=0.000)was significantly lower in the MitraClip group than in surgical group. Conclusion:Despite a higher risk profile in the MitraClip patients compared to surgical intervention

efficacy and safety of MitraClip system is not worse than surgeryin the treatment of mitral regurgitation.